Explore the words cloud of the ClarifyLupus project. It provides you a very rough idea of what is the project "ClarifyLupus" about.
The following table provides information about the project.
CLARIFY ANALYTICAL LDA
|Coordinator Country||Portugal [PT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-03-01 to 2019-08-31|
Take a look of project's partnership.
|1||CLARIFY ANALYTICAL LDA||PT (EVORA)||coordinator||50˙000.00|
The difficulty on diagnosing lupus is due not only to the occurrence of overlapping symptoms with other autoimmune diseases but also to the unavailability of a lab test to confirm or rule out Lupus. The autoimmune disease is devastating, and the later it is diagnosed, the worse are the irreversible damages to the patients. In the USA alone, there are 13.8M people with Lupus and overlapping diseases and 2,6M new cases of these diseases are diagnosed each year. These diseases affect more than 25M people in the EU. We have developed a technology capable of identifying and quantifying altered proteins that play a key role in the onset of Lupus. Our product ClarifyLupus is a diagnostic test that is effective since the early stages of the disease. Although our competitors are conducting research on Lupus biomarker discovery, they all are focused in autoantibodies biomarker discovery that are highly unspecific among Lupus-confounding diseases. In contrast we have a Lupus-specific biomarker that enables the Lupus diagnosis much earlier than our competitors. We have passed the proof-of-concept stage where our diagnosis methodology was tested in blood samples and in January 2018 we have secured the Portuguese ethical committee approval to perform clinical assays, and are recruiting 50 patients until the end of the year. In April 2018 we secured a Letter of Support from the Egas Moniz Hospital in Lisbon, stating the importance and market disruption of ClarifyLupus. Clarify Analytical was founded in 2017 by Alexandra Antunes and João Rodrigues, two expert technologists in the fields of toxicology and mass spectroscopy, supported by 3 team members. The start-up was selected for the prestigious CoHiTech acceleration program in Portugal, focused on business and technology go-to-market. ClarifyLupus will be the breakthrough for Lupus diagnosis which will allow Lupus patients to be treated earlier, extending their lives by decades and improving their quality.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLARIFYLUPUS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CLARIFYLUPUS" are provided by the European Opendata Portal: CORDIS opendata.
Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.Read More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More
IOT and cloud computing for online medical analysis service platformRead More